Alabama Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Alabama

Alabama Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Alabama Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Alabama Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.


Abstract: Doxorubicin is a commonly used chemotherapy agent in the treatment of malignant mesothelioma. Onconase is an experimental (not approved by the FDA) drug that has shown activity against malignant mesothelioma. The purpose of this study is to determine whether Onconase, when administered into the blood stream, is better than injection of Doxorubicin into the blood stream for the treatment of malignant mesothelioma. Approximately 160 patients across the country will be enrolled on this study. These patients will receive either Onconase by intravenous infusion over 30 minutes weekly, or Doxorubicin every 3 weeks for a maximum of 6 doses. Treatment will continue for at least 18 weeks or until the tumor is no longer responding to treatment. After treatment has been stopped, patients will be monitored by a physician to determine late side effects and future therapy. 

Tags: Antineoplastic, Doxorubicin, Human Therapy Evaluation, Mesothelioma, Neoplasm /cancer Chemotherapy Clinical Trial Clinical Research, Human Subject

  • Followup Grant: 5M01RR000032-400649
  • Followup Grant: 5M01RR000032-410649
  • Followup Grant: 5M01RR000032-420649

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
More Information

Condition: Lung Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Sarcoma
Intervention: Drug: L-alanosine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

Hospitals and Cancer Centers

University of Alabama at Birmingham Comprehensive Cancer Center

1824 6th Ave. S. 236 TI
Birmingham, AL


Dr. Robert J. Cerfolio

Thoracic Surgeon
University of Alabama at Birmingham
Department of Cardiothoracic Surgery
703 19th Street
Birmingham, Alabama 35294

Henderson v. Meadwestvaco Corp.
1070522, 1070497, 1070509, SUPREME COURT OF ALABAMA, March 20, 2009, Released

GMC v. Kilgore
1002149 , SUPREME COURT OF ALABAMA, December 20, 2002, Released

Southern Bakeries, Inc. v. Knipp
1010743 , SUPREME COURT OF ALABAMA, December 13, 2002, Released

Greene v. Csx Transp.
1010357 , SUPREME COURT OF ALABAMA, August 30, 2002, Released

Ex parte Wilkerson
1990769, SUPREME COURT OF ALABAMA, September 8, 2000, Released

Wilkerson v. Burlington N. R.R.
2980962, COURT OF CIVIL APPEALS OF ALABAMA, September 24, 1999, Released

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name (required)

State (required)

Your Email (required)



A unique, inspirational book by a fellow sufferer and dedicated Author and Educator. Written from the heart and with understanding there are guidelines to help enhance your body's own immune system. Through knowledge we gain power! This gives us strength to strive to achieve our best possible outcome.

I feel so much more hopeful every time I hear about survivors and especially them doing so with immune boosting therapies and other non traditional methods. Thank You so very much!
More Testimonials


Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly, Inc. All of the information provided on this website or by an employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.


  • Centers for Disease Control and Prevention (CDC)

    Dr. K.M. Bang, Dr. J.M. Mazurek, Dr. J. Wood JM

  • Creighton University School of Medicine

    Brian L. Loggie, MD, FACS

  • David Geffen School of Medicine, UCLA

    Dr. C.R. Logg, Dr. N. Kasahara, Dr. K.E. Rosenzweig

  • Icahn School of Medicine at Mount Sinai, New York

    Dr. P.A. Zucali, Dr. M. Perrino, Dr. E. Lorenzi, Dr. G.L. Ceresoli, Dr. F. De Vincenzo, Dr. M. Simonelli , Dr. L. Gianoncelli

  • Mayo Clinic

    Zachary S. DePew, M.D., Dennis Wigle, M.D., Ph.D, John J. Mullon, M.D., Francis C. Nichols, M.D., Claude Deschamps, M.D., Fabien Maldonado, M.D.

  • Moffitt Cancer Center, Tampa, FL

    Dr. J. Wong, Dr. A.L. Koch, Dr. J.K. Deneve, Dr. W. Fulp, Dr. T. Tanvetyanon, Dr. S. Dessureault

  • National Institute for Occupational Safety & Health

    Dr. R.D. Daniels, Dr. T.L. Kubale, Dr. J.H. Yiin, Dr. M.M. Dahm, Dr. T.R. Hales, Dr. D. Baris, Dr. S.H. Zahm, Dr. J.J. Beaumont,

  • University of Chicago, Medical Center

    Dr. Z.E. Labby, Dr. S.G. Armato 3rd, Dr. J.J. Dignam, Dr. C. Straus, Dr. H.L. Kindler, Dr. A.K. Nowak, Dr. Aliya N. Husain, Dr. M. Kamran Mirza, Dr. Yiqing Chi, Dr. Redouane Boumendjel

  • University of Maryland School of Medicine

    Dr. H.R. Alexander, Dr. D.L. Bartlett, Dr. J.F. Pingpank, Dr. S.K. Libutti, Dr. R. Royal, Dr. M.S. Hughes, Dr. M. Holtzman

  • University of Hawaii Cancer Center

    Dr. Michele Carbone, Dr. Harvey Pass, Dr. H. Yang, Dr. T. Krausz, Dr. J.R. Testa, Dr. G. Gaudino

  • Wake Forest University School of Medicine

    Edward A. Levine, MD, FACS, John H. Stewart IV, MD, FACS, Perry Shen, MD, FACS, Gregory B. Russell, MS


  • Glenfield Hospital, United Kingdom

    Dr. A. Nakas, Dr. David Waller

  • Karolinska Institutet, Stockholm, Sweden

    Dr. A. Szulkin, Dr. G. Nilsonne, Dr. F. Mundt, Dr. A.M. Wasik, Dr. P. Souri, Dr. A. Hjerpe, Dr. K. Dobra

  • Le laboratoire d'Anatomie Pathologique, France

    Dr. Francoise Galateau-Salle
    Dr. Nolwenn Stang

  • National Kyushu Cancer Center, Fukuoka, Japan

    Dr. M. Shimokaw, Dr. S. Hasegawa, Dr. K. Fukuoka, Dr. M. Okada, Dr. K. Yokoi, Dr. F. Tanaka, Dr. T. Yamanaka, Dr. T. Daimon, Dr. T. Nakano

  • Princess Margaret Cancer Centre, Canada

    Dr. R. Feld, Dr. N. Leighl, Dr. I. Opitz, Dr. M. Anraku, Dr. M.S. Tsao, Dr. D.M. Hwang, Dr. A. Hope

  • San Raffaele Science Institute, Milano, Italy

    Dr. V. Volta, Dr. E. Ranzato, Dr. S. Martinotti, Dr. S. Gallo, Dr. M.V. Russo, Dr. L. Mutti, Dr. S. Biffo, Dr. B. Burlando

  • University Hospital of Siena, Siena, Italy

    Dr. L. Calabrò, Dr. A. Morra, Dr. E. Fonsatti, Dr. O. Cutaia, Dr. G. Amato Dr. D. Giannarelli, Dr. A.M. Di Giacomo, Dr. R. Danielli, Dr. M. Altomonte, Dr. L. Mutti, Dr. M. Maio

  • University of Edinburgh, Edinburgh

    Dr. N. Macleod, Dr. A. Price, Dr. N. O'Rourke, Dr. M. Fallon, Der. B. Laird

  • University of New South Wales, Australia

    Dr. K. Pillai, Dr. A. Ehteda, Dr. J. Akhter, Dr. T.C. Chua, Dr. D.L. Morris

  • University of Sydney, Australia

    Dr. G. Reid, Dr. M.E. Pel, Dr. M.B. Kirschner, Dr. Y.Y. Cheng, Dr. N. Mugridge, Dr. J. Weiss, Dr. M. Williams, Dr. C. Wright, Dr. J.J. Edelman, Dr. M.P. Vallely, Dr. B.C. McCaughan, Dr. S. Klebe, Dr. H. Brahmbhatt, Dr. J.A. MacDiarmid, Dr. N. van Zandwijk